BioSpace News Archive

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Thursday, May 7, 2020.

Fruit Street Health, a leading telehealth company funded and guided by physicians, today announced the launch of CovidMD™ (www.CovidMD.com), a risk assessment, triage, and telemedicine platform created to help the healthcare system safely and efficiently respond to the COVID-19 pandemic.

NeuroMetrix, Inc. reported financial and business highlights for the quarter ended March 31, 2020.

Merck, known as MSD outside the United States and Canada, announced the resubmission of its supplemental Biologics License Applications to the U.S. Food and Drug Administration to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include a 400 mg dose infused over 30 minutes every six weeks, in addition to the currently approved dose of 200 mg every three weeks.

Industry leader with global clinical development expertise to help guide Imara’s clinical advancement

Axogen, Inc. announced preliminary first quarter 2020 revenue, provided a business update on its actions in response to the COVID-19 pandemic, and announced the dismissal of its class-action lawsuit.

Two Virtual Posters Highlight New ANJESO Clinical Results, Along with Health Resource Utilization Data, When Administered Preoperatively Following Total Knee Arthroplasty

During the ongoing COVID-19 pandemic, people across Arkansas are facing challenges that extend beyond medical care and includes basic daily needs.

During the ongoing COVID-19 pandemic, people across Texas are facing challenges that extend beyond medical care and include basic daily needs such as food and essential supplies.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2020 financial results on Thursday, April 30, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. an